Listen Here:
Click or simply search “Sigma Nutrition” on your podcast platform of choice.
Or listen directly on the Sigma website here.
Introduction
GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery. But what happens after the weight is lost? And can we really talk about success without talking about maintenance?
While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next. Can lifestyle interventions alone sustain weight loss after GLP-1 cessation? How do metabolic adaptations and behavioral relapse factor in? And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications?
In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management.
Related resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- Enroll in the next cohort of our Applied Nutrition Literacy course
- [05:17]Understanding weight loss maintenance
- [08:44]Defining success in weight loss maintenance
- [11:54]Predictors of maintenance: self-monitoring and behavioral strategies
- [23:37]Pharmacological interventions: GLP-1 receptor agonists
- [31:06]Dietary considerations for those taking GLP-1 RAs
- [37:07]Addressing misconceptions about weight loss drugs
- [42:48]Final thoughts and takeaways
- [48:49]Key ideas (Premium-only)
Guest Information
Click through to your app of choice to listen and subscribe:
As the lead dietitian for the Mayo Clinic Diet, she provides guidance rooted in evidence-based principles. She hosts the Mayo Clinic On Nutrition podcast and co-authored The Mayo Clinic Diet: Weight Loss Medications Edition.
Danny Lennon has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, and he is the founder of Sigma Nutrition.
Danny is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.
Introduction to this Episode
GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery.
But what happens after the weight is lost?
And can we really talk about success without talking about maintenance?
While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next.
- Can lifestyle interventions alone sustain weight loss after GLP-1 cessation?
- How do metabolic adaptations and behavioral relapse factor in?
- And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications?
In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management.
Useful Terminology for this Episode
- Weight Loss Maintenance: The sustained keeping off of weight that has been lost. Often defined in research as maintaining a ≥ 5% reduction in initial body weight for at least one year.
- Success in weight loss maintenance is typically measured by the extent of weight kept off over the long term rather than short-term loss.
- Metabolic Adaptation: Physiological changes following weight loss that reduce energy expenditure and increase hunger, favoring weight regain. This includes a drop in resting metabolic rate and shifts in appetite-regulating hormones (e.g., ↓leptin, ↑ghrelin), making weight maintenance harder than initial loss.
- Behavioral Drift: A gradual relaxation of adherence to healthy behaviors over time. After weight loss, people may slowly slip back into old habits (larger portions, less activity, etc.), which can lead to weight regain if not recognized and corrected.
- GLP-1 Receptor Agonists (GLP-1 RAs): A class of medications that suppress appetite and slow gastric emptying to aid weight loss.
- Examples include semaglutide and liraglutide. These drugs have recently been approved for obesity treatment due to their significant weight reduction effects.
- Food Noise: A colloquial term used to describe persistent background thoughts, cravings, and impulses related to food. Individuals with high food noise experience frequent urges to eat. GLP-1 RAs are noted in this episode to dramatically reduce “food noise”, helping patients experience normal satiety signals and fewer obsessive food thoughts.
- National Weight Control Registry (NWCR): A long-running research registry tracking people who have successfully maintained significant weight loss.
